SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
ChromaDex Corporation (CDXC), a Delaware corporation, filed this Current Report on Form 8-K on November 12, 2019. The filing discloses the entry into a material definitive agreement to secure business financing. Note: The request metadata referenced "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics and Debt Structure
The filing details a new revolving credit facility with the following terms:
- Facility Amount: Up to $7,000,000 aggregate principal.
- Lender: Western Alliance Bank.
- Interest Rate: Floating rate equal to the greater of 4.75% or the Prime Rate, plus 1.50 percentage points. An additional 5.00 percentage points applies during an event of default.
- Maturity Date: November 12, 2021.
- Upfront Costs: $35,000 facility fee and $900 due diligence fee paid upon execution.
- Termination Fee: $70,000 if terminated prior to November 12, 2020 (waived if refinanced with the Lender).
- Collateral: Security interest in substantially all current and future personal property assets, including intellectual property.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the period.
Material Changes and Covenants
This agreement represents a new material debt obligation. The Borrowers (ChromaDex Corporation and its subsidiaries) are subject to:
- Financial Covenants: Maintenance of a quick ratio and minimum liquidity.
- Operational Covenants: Affirmative and restrictive covenants regarding financial statement delivery, inventory maintenance, tax payments, insurance, and restrictions on additional indebtedness or business combinations.
- Default Remedies: The Lender may declare all obligations due and payable upon failure to meet payment obligations, breach of covenants, or a material adverse change.
Outlook and Use of Proceeds
The Borrowers intend to use the proceeds from the credit line for working capital needs and to fund general business requirements. The filing does not contain specific forward-looking guidance, management commentary on future performance, or details on unusual items beyond the financing agreement.
Investor Verification Checklist
- Verify the company's current liquidity position to ensure compliance with the new quick ratio and minimum liquidity covenants.
- Review the full text of the Credit Agreement (to be filed as an exhibit to the 2019 Form 10-K) for detailed default triggers and restrictive covenants.
- Monitor the company's ability to service the floating interest rate, which is tied to the Prime Rate plus a spread.
- Confirm the status of the $70,000 termination fee obligation if the facility is not utilized or refinanced before November 2020.